alexsl
- Teva Pharmaceutical (NYSE:TEVA) was upgraded to Overweight from Neutral at J.P. Morgan on margin clarity for 2027 to 2028, post cost-cutting program.
- Analysts at J.P. Morgan said that Teva’s margin trajectory in 2026/27 was their primary concern as it struggles with step-down